The research is done. Need a company to assist in carrying out clinical trials to quickly get this approved and save many lives.
Methylene Blue is currently in use as a dye and as a medication in the body so is a medically approved drug.
As COVID-19(Coronavirus) ravages the world, a quick, novel, cost effective cure for this malaise needs to be found.
Being a pulmonologist (lung specialist) in India, I have been treating pneumonia, other respiratory ailments and Tuberculosis patients (with XDR & MDR TB) for more than 42 years.
As a pioneer of this technique, I’ve achieved remarkable success in treating my patients with Methylene Blue and with documented evidence over the years. When used in sub lingual and nebulised form M.B. helps remarkably in clearing alveolar capillary block.
Covid causes a silent hypoxia wherein patients despite having acute hypoxia (low oxygen saturation spO2) show no clinical symptoms. Patient is not dyspnoeic in spite of having very low oxygen saturation. These soon escalate to a cytokine storm and patient goes in the irreversible phase of the respiratory distress.
Covid patients show resemblance to methemoglobinemia. MB is considered an approved drug of choice for methemoglobinemia. Additionally, M.B. has a strong antifibrotic action and is very fast acting.
Given the above presentations, Methylene Blue can be used as a treatment to all Coronavirus symptomatic patients & as a prophylactic drug to all vulnerable population. Used in low dosage (as prescribed below) it shows no significant side effects (less than 2% of patients complained of irritation in the nose/nausea for a day which subsided on its own). Given its low cost, it is also a viable regime for poorer countries like India. A number of patients(with varying levels of respiratory distress) have been treated using MB in nebulised/sub-lingual for over the course of my years of practice.
Potential Treatment regime for the novel Coronavirus (Covid-19)
Primary course of administration is in Nebulized form and Sublingually together. For patients with severe Cyanosis (oxygen levels less than 85%), IV may be required based on the clinical condition of the patient.
Administration steps as below (under medical supervision only)
Methylene Blue to be administered as inhalation through a nebulizer (Primary line of treatment)
Nebulization to be given through a nasal mask
Sublingual administration to be done in parallel
Depending on the level of respiratory distress, add Budesonide + Salbutamol + Ipratropium (Budencort & Duolin are commonly available drugs with the same composition in India) to reduce bronchial oedema and dilatation of bronchi
Dr Deepak Golwalkar
Bhavnagar
Gujarat
India
https://hub.bio.org/topic/treatment-coronavirus-using-methylene-blue-dr-deepak-golwalkar
Methylene Blue is currently in use as a dye and as a medication in the body so is a medically approved drug.
As COVID-19(Coronavirus) ravages the world, a quick, novel, cost effective cure for this malaise needs to be found.
Being a pulmonologist (lung specialist) in India, I have been treating pneumonia, other respiratory ailments and Tuberculosis patients (with XDR & MDR TB) for more than 42 years.
As a pioneer of this technique, I’ve achieved remarkable success in treating my patients with Methylene Blue and with documented evidence over the years. When used in sub lingual and nebulised form M.B. helps remarkably in clearing alveolar capillary block.
Covid causes a silent hypoxia wherein patients despite having acute hypoxia (low oxygen saturation spO2) show no clinical symptoms. Patient is not dyspnoeic in spite of having very low oxygen saturation. These soon escalate to a cytokine storm and patient goes in the irreversible phase of the respiratory distress.
Covid patients show resemblance to methemoglobinemia. MB is considered an approved drug of choice for methemoglobinemia. Additionally, M.B. has a strong antifibrotic action and is very fast acting.
Given the above presentations, Methylene Blue can be used as a treatment to all Coronavirus symptomatic patients & as a prophylactic drug to all vulnerable population. Used in low dosage (as prescribed below) it shows no significant side effects (less than 2% of patients complained of irritation in the nose/nausea for a day which subsided on its own). Given its low cost, it is also a viable regime for poorer countries like India. A number of patients(with varying levels of respiratory distress) have been treated using MB in nebulised/sub-lingual for over the course of my years of practice.
Potential Treatment regime for the novel Coronavirus (Covid-19)
Primary course of administration is in Nebulized form and Sublingually together. For patients with severe Cyanosis (oxygen levels less than 85%), IV may be required based on the clinical condition of the patient.
Administration steps as below (under medical supervision only)
Methylene Blue to be administered as inhalation through a nebulizer (Primary line of treatment)
Nebulization to be given through a nasal mask
Sublingual administration to be done in parallel
Depending on the level of respiratory distress, add Budesonide + Salbutamol + Ipratropium (Budencort & Duolin are commonly available drugs with the same composition in India) to reduce bronchial oedema and dilatation of bronchi
Dr Deepak Golwalkar
Bhavnagar
Gujarat
India
https://hub.bio.org/topic/treatment-coronavirus-using-methylene-blue-dr-deepak-golwalkar
